Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

Por Phillips, D C, Xiao, Y, Lam, L T, Litvinovich, E, Roberts-Rapp, L, Souers, A J, Leverson, J D
Publicado no Blood Cancer J (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

Por Phillips, D C, Xiao, Y, Lam, L T, Litvinovich, E, Roberts-Rapp, L, Souers, A J, Leverson, J D
Publicado no Blood Cancer J (2016)

OS1.2 Stability of EGFR amplification in glioblastoma is differentially impacted based on therapeutic pressure

Por Ahluwalia, M, Narita, Y, Muragaki, Y, Gan, H, Merrell, R, van den Bent, M, Roberts-Rapp, L, Guseva, M, Ansell, P, Lassman, A
Publicado no Neuro Oncol (2018)

P06.02 Transcriptional profiling to identify determinants associated with response to ABT-414 in patients with glioblastoma

Por van den Bent, M., Gan, H., Reardon, D. A., Papadopoulos, K. P., Merrell, R., Kumthekar, P., Roberts-Rapp, L., Holen, K., Ansell, P., Lassman, A. B.
Publicado no Neuro Oncol (2016)

P01.071 Genomic profiling identifies tubulin mutations that may predict response to depatuxizumab mafodotin in patients with glioblastoma

Por Lassman, A B, Roberts-Rapp, L, He, L, Lu, X, Zha, Z, Bhathena, A, Ansell, P J, Gan, H K, Scott, A M, van den Bent, M
Publicado no Neuro Oncol (2018)